TABLE 1.
Demographics and clinical characteristics at baseline.
| Overall N (%) | Atovaquone (n = 41) N (%) | Placebo (n = 19) N (%) | p Value | |
|---|---|---|---|---|
| Gender | ||||
| Male | 38 (63) | 26 (63) | 12 (63) | 1.0 |
| Race | ||||
| White | 46 (77) | 31 (76) | 15 (79) | 1.0 |
| Black | 8 (13) | 6 (15) | 2 (11) | |
| Ethnicity | ||||
| Hispanic | 42 (70) | 29 (71) | 13 (68) | 1.0 |
| Age, mean yeas (IQR) | 50.9 (41.9, 59.6) | 51.64 (42.5, 60.8) | 49.4 (41, 59.6) | 0.56 |
| BMI, mean | 32.78 (27,36.5) | 32.65(27.1, 35.9) | 33.07 (26.8, 37.1) | 0.86 |
| Co-morbidities | ||||
| Hypertension | 38 (63) | 26 (63) | 12 (63) | 1.0 |
| Diabetes | 38 (63) | 30 (73) | 8 (42) | 0.04 |
| Obesity | 23 (38) | 15 (37) | 8 (42) | 0.78 |
| Chronic kidney disease | 20 (33) | 12 (29) | 8 (42) | 0.38 |
| Lung disease a | 12 (20) | 10 (24) | 2(11) | 0.31 |
| Heart disease b | 7(12) | 5 (12) | 2 (11) | 1.0 |
| Cancer | 6 (10) | 3 (7) | 3 (16) | 0.37 |
| Transplant | 5 (8) | 2 (5) | 3 (16) | 0.31 |
| Liver disease | 5 (8) | 4 (10) | 1 (5) | 1.0 |
| Vascular | 4 (7) | 2 (5) | 2 (11) | 0.23 |
| Other c | 3 (5) | 1 (2) | 2 (11) | 0.26 |
| Other treatment | ||||
| On remdesivir | 27 (66) | 9 (47) | 0.26 | |
| On dexamethasone | 30 (73) | 14 (74) | 1 | |
| Plasma | 4 (10) | 1 (5) | 1 | |
| Other characteristics | ||||
| Days from symptom onset, mean days (IQR) | 5.15 (4,6) | 5.24 (4,7) | 4.95 (4,6) | 0.56 |
| Oxygen status at baseline | 0.57 | |||
| Room air | 17 (28.3) | 10 (24.4) | 7 (36.8) | |
| Low flow oxygen | 40 (66.7) | 29 (70.7) | 11 (57.9) | |
| High flow oxygen | 3 (5) | 2 (4.9) | 1 (5.3) | |
a
Chronic obstructive pulmonary disease, asthma, smoking.
b
Congestive heart failure, myocardial infarction, coronary artery disease, cardiomyopathy.
c
Autoimmune, connective tissue, peptic ulcer, HIV\.